PharmaCyte Biotech, Inc.

- 17 NOV 2015
PharmaCyte Biotech Obtains Orphan Drug Designation in Europe for Its Pancreatic Cancer Treatment
SILVER SPRING, Md., Nov. 17, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that, upon the recommendation of the European Medicines Agency (EMA), the European Commission has granted the Orphan Drug designation
Read more →
- Posted in
- News
- 11 NOV 2015
PharmaCyte Biotech Scientific Advisory Board Member Named Clinical Director of Prestigious Boston Cancer Center
SILVER SPRING, Md., Nov. 10, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Manuel Hidalgo, MD, PhD, an internationally respected oncologist and a member of PharmaCyte ’s Scientific Advisory Board, has
Read more →
- Posted in
- News
- 23 OCT 2015
PharmaCyte Biotech Management Interviewed to Discuss Key Aspects of New Pancreatic Cancer Clinical Trial Design
SILVER SPRING, MD, October 23, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the release of a recorded interview with Chief Executive Officer Kenneth L. Waggoner and Chief Operating Officer Dr.
Read more →
- Posted in
- News
- 21 OCT 2015
PharmaCyte Biotech Clinical Trial Designed to Expand Standard of Care Therapy for Pancreatic Cancer
SILVER SPRING, Md., Oct. 21, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the new trial design for its upcoming clinical trial in patients with advanced pancreatic cancer using PharmaCyte’s treatment (Cell-in-a-Box®
Read more →
- Posted in
- News
- 05 OCT 2015
Imaging Endpoints Founder Discusses Role in PharmaCyte Biotech’s Unique Approach to Pancreatic Cancer for Upcoming Clinical Trial
SILVER SPRING, MD, October 5, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released today the third in a series of articles that will serve to educate the public on its technology and
Read more →
- Posted in
- News
- 01 OCT 2015
PharmaCyte Biotech Retains Industry Expert to Monitor Short Sellers and Market Makers
SILVER SPRING, Md., October 1, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell in a Box ®, announced today that BUYINS.NET, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and
Read more →
- Posted in
- News
- 28 SEP 2015
PharmaCyte Biotech’s Encapsulation Technology Could Address Unmet Medical Need
SILVER SPRING, MD, September 28, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, released today the second in a series of articles that will serve to educate the public on its technology and how
Read more →
- Posted in
- News
- 25 SEP 2015
PharmaCyte Biotech Hires Industry-Leading Firm to Assist with Investigational New Drug Application
SILVER SPRING, MD, September 25, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes announced today that it has contracted with Chamow & Associates, located in the San Francisco Bay Area, to assist with the Chemistry, Manufacturing and Control (CMC) regulatory
Read more →
- Posted in
- News
- 23 SEP 2015
PharmaCyte Biotech Discusses Pancreatic Cancer Treatment for Upcoming Phase 2b Human Clinical Trial
SILVER SPRING, Md., Sept. 22, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released today the first in a series of articles that will serve to educate the public on its technology and how
Read more →
- Posted in
- News
- 09 SEP 2015
PharmaCyte Biotech Begins Phase 2b Clinical Trial Push With Imaging Endpoints Contract for Radiological Imaging
SILVER SPRING, Md., Sept. 09, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has contracted with Imaging Endpoints in Scottsdale, Arizona, to perform radiologic imaging that will be required for
Read more →
- Posted in
- News

Press Releases